HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Amneal Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Amneal Pharmaceuticals Intelligence Report

Generated from 9 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 71%

Evidence

51 items

Sources

10

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Amneal Pharmaceuticals maintains an active intelligence profile across Oncology, Chemotherapy, Psychiatry, Antipsychotic, Obstetrics. 9 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 71% across 2 tracked sources. Highest-priority development: FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Amneal Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — SODIUM BICARBONATE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    Withdrawn | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Rare Disease Drug Approvals

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 431 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LEVOTHYROXINE SODIUM (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SODIUM BICARBONATE (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Rare Disease Drug Approvals

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — METHYLERGONOVINE MALEATE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • CDER proposes to withdraw approval of TAVNEOS

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approval Update for Methylergomovine Maleate by Amneal Pharmaceuticals

    Obstetrics · Uterotonics

  • FDA Approval Update for Hydrocodone Bitartrate and Ibuprofen by Amneal Pharmaceuticals

    Pain Management · Opioid Combination

  • FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen

    Pain Management · Opioid Combination

  • Amneal Pharmaceuticals Receives AP Status for Methotrexate Sodium ANDA210040

    Oncology · Chemotherapy

  • FDA Grants Supplement Approval for Lurasidone Hydrochloride by Amneal Pharmaceuticals

    Psychiatry · Antipsychotic

  • Amneal Pharmaceuticals submits ANDA for Milnacipran Hydrochloride

    Neurology · Pain Management

  • FDA Approval for Amneal's Tramadol Hydrochloride Supplement

    Pain Management · Analgesic

  • FDA Approval Letter for Hydrocodone Bitartrate and Acetaminophen

    Pain Management · Opioid Combination

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.